Neumora Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
ARCH Venture Funds and affiliated entities continue to hold a substantial beneficial ownership stake in Neumora Therapeutics, Inc., as detailed in a recent Schedule 13D amendment.
NASDAQ
ARCH Venture Fund XII increased its holdings in Neumora Therapeutics, Inc. by purchasing 1.9 million shares for approximately $5 million.